<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00009971</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068428</org_study_id>
    <secondary_id>CCUM-9940</secondary_id>
    <secondary_id>NCI-T99-0112</secondary_id>
    <nct_id>NCT00009971</nct_id>
  </id_info>
  <brief_title>Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Trial Of Fenretinide (NSC-374551; IND-40, 294) In Patients With Relapsed Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of fenretinide in treating patients who have&#xD;
      recurrent small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of fenretinide, in terms of complete and partial response rates,&#xD;
      duration of response, and survival, in patients with recurrent small cell lung cancer.&#xD;
&#xD;
      II. Determine the toxicity of this regimen in these patients. III. Correlate the induction of&#xD;
      apoptosis or the expression of molecular mediators of apoptosis in tumor cells with response&#xD;
      rates, response duration, and survival in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days&#xD;
      for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenretinide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed recurrent small cell lung cancer (SCLC)&#xD;
             after platinum-containing chemotherapy regimen with or without thoracic radiotherapy&#xD;
&#xD;
               -  Limited stage or extensive stage SCLC&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR&#xD;
&#xD;
               -  At least 10 mm with spiral CT scan&#xD;
&#xD;
          -  No pleural effusions, bone metastases, brain metastases, or abnormal radionucleotide&#xD;
             scans as sole evidence of disease&#xD;
&#xD;
          -  No symptomatic or uncontrolled brain or leptomeningeal disease&#xD;
&#xD;
               -  Previously treated brain metastases allowed if neurologically stable&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 70,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for 1 month before, during, and for&#xD;
             2 months after study&#xD;
&#xD;
          -  No pre-existing retinal degenerative disease (e.g., retinitis pigmentosa or associated&#xD;
             disorders)&#xD;
&#xD;
          -  No other serious concurrent illness&#xD;
&#xD;
          -  No other malignancy within the past 5 years except localized nonmelanoma skin cancer&#xD;
             or carcinoma in situ&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent steroids allowed at stable dose&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to study lesions&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic retinoid or carotenoid therapy&#xD;
&#xD;
          -  No concurrent anticonvulsants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory P. Kalemkerian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>limited stage small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenretinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

